Navigation Links
AUTOSTAT™II Anti-Gliadin IgG ELISA

ProductsAUTOSTAT™II Anti-Gliadin IgG ELISA
Company Hycor Biomedical Inc.
Item AUTOSTAT™II Anti-Gliadin IgG ELISA
Features 
Description Enzyme-linked immunosorbent assay method for the semi-quantitative determination of specific IgG autoantibodies to gliadin in human serum. The results of the anti-Gliadin IgG assay can be used as an aid in the diagnosis of diseases associated with elevated levels of anti-Gliadin antibodies including Coeliac Disease. Levels of these autoantibodies are one indicator in a multi-factorial diagnostic regime. This kit has been validated for use with the HYCOR HYTEC automated EIA instrument, and can also be used in a manual assay. For in vitro diagnostic use only.
Info Hycor Biomedical Inc.
Customer Service: (800) 382-2527
Web site: http://www.hycorbiomedical.com

Related medicine products :

1. AUTOSTAT™II Anti-Gliadin IgA ELISA
2. AUTOSTAT™II Anti-GBM
3. Anti-Gliadin IgG & IgA (Ab) EIA Gastrointestinal Markers 027-GD77 Celiac Disease Food Allergy
4. Anti-Gliadin IgG (Ab) EIA Gastrointestinal Markers 027-GD16 Celiac Disease Food Allergy
5. Anti-Gliadin IgA (Ab) EIA Gastrointestinal Markers 027-GD17 Celiac Disease Food Allergy
6. SCANLISA Anti-Gliadin IgG Assay
7. SCANLISA Anti-Gliadin IgA Assay
8. Microplate ELISA Washers - Manual Microplate Washer
9. Microplate ELISA Washers - Automated Microplate Washer
10. Vitamin D 25-Hydroxy ELISA 026-AC-57F1 Bone and Mineral Metabolism
11. RELISA ANA Screening System
Other Medicine News:Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 2Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 3Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 4Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 5Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 6Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 7Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 8Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 9Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 10Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 11Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 12Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 13Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 14Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 15Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 16Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 17Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 18Health News:Rheumatoid Arthritis May Harm Gums 2Health News:Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R) 2Health News:NASA-Enhanced Dust Storm Predictions to Aid Health Community 2Health News:NASA-Enhanced Dust Storm Predictions to Aid Health Community 3
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8CBI Announces FDA Participation at Upcoming Forum on Clinical Trial Investigator Portals 14631 1CBI Announces FDA Participation at Upcoming Forum on Clinical Trial Investigator Portals 14631 2CBI Announces FDA Participation at Upcoming Forum on Clinical Trial Investigator Portals 14631 3Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 1Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 2Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 3Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 4Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 5Breast Health is a Year Round Priority 3A New Technology Identifies Risk of Breast Cancer in Younger Women 5779 1Breast Health is a Year Round Priority 3A New Technology Identifies Risk of Breast Cancer in Younger Women 5779 2Breast Health is a Year Round Priority 3A New Technology Identifies Risk of Breast Cancer in Younger Women 5779 3